In this study, one adverse effect was a rise in serum triglycerides and free fatty acids [114], highlighting that further studies investigating the role of PCSK9 in alcoholic liver disease are needed to clarify if PCSK9 inhibitors have the potential to improve alcoholic liver disease. The gene discussed is PCSK9; the disease is alcoholic liver diseases.